THERAPEUTICS Silencing psoriasis

被引：26

作者：

Crow, James Mitchell

机构：

[1] James Mitchell Crow is a freelance science writer based in Melbourne,

[2] Australia.,undefined

来源：

NATURE | 2012年 / 492卷 / 7429期

关键词：

MONOCLONAL-ANTIBODY; EFFICACY; SAFETY;

D O I：

10.1038/492S58a

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

070301 [无机化学]; 070403 [天体物理学]; 070507 [自然资源与国土空间规划学]; 090105 [作物生产系统与生态工程];

摘要：

The latest drugs hold fantastic promise for people with severe psoriasis. But where are the treatment options for the far larger number with less serious cases?

引用

页码：558 / 559

页数：2

共 7 条

[1]

Krueger G, 2001, ARCH DERMATOL, V137, P280

[2]

Anti-Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis [J].

Leonardi, Craig ;

Matheson, Robert ;

Zachariae, Claus ;

Cameron, Gregory ;

Li, Linda ;

Edson-Heredia, Emily ;

Braun, Daniel ;

Banerjee, Subhashis .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (13) :1190-1199

[3]

Leonardi CL, 2008, LANCET, V371, P1665, DOI 10.1016/S0140-6736(08)60725-4

[4]

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study [J].

Papp, K. A. ;

Menter, A. ;

Strober, B. ;

Langley, R. G. ;

Buonanno, M. ;

Wolk, R. ;

Gupta, P. ;

Krishnaswami, S. ;

Tan, H. ;

Harness, J. A. .

BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 (03) :668-677

[5]

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial [J].

Papp, Kim ;

Cather, Jennifer C. ;

Rosoph, Les ;

Sofen, Howard ;

Langley, Richard G. ;

Matheson, Robert T. ;

Hu, ChiaChi ;

Day, Robert M. .

LANCET, 2012, 380 (9843) :738-746

[6]

Brodalumab, an Anti-Interleukin-17-Receptor Antibody for Psoriasis [J].

Papp, Kim A. ;

Leonardi, Craig ;

Menter, Alan ;

Ortonne, Jean-Paul ;

Krueger, James G. ;

Kricorian, Gregory ;

Aras, Girish ;

Li, Juan ;

Russell, Chris B. ;

Thompson, Elizabeth H. Z. ;

Baumgartner, Scott .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (13) :1181-1189

[7]

Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study [J].

Rich, P. ;

Sigurgeirsson, B. ;

Thaci, D. ;

Ortonne, J. -P. ;

Paul, C. ;

Schopf, R. E. ;

Morita, A. ;

Roseau, K. ;

Harfst, E. ;

Guettner, A. ;

Machacek, M. ;

Papavassilis, C. .

BRITISH JOURNAL OF DERMATOLOGY, 2013, 168 (02) :402-411

← 1 →